Expert Answers to Key Questions on Current and Emerging BTK Inhibitor Therapies for CLL and MCL

In this episode, Jeff P. Sharman, MD; Matthew S. Davids, MD, MMSc; and Anthony Mato, MD, MSCE, answer questions from a live CCO webinar on current best practices and  emerging strategies in BTK inhibitor therapy for patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), with questions including:For patients with CLL, when should acalabrutinib-, ibrutinib-, or venetoclax-based regimens be considered?What is the optimal therapy for a patient with del(17p) CLL?When should an anti-CD20 antibody be added to BTK inhibitor therapy for patients with CLL?What are best practices in the use of BTK inhibitors for patients with MCL?How can BTK inhibitor resistance occur?How might investigational noncovalent BTK inhibitors be used should they be approved?What are key adverse events with BTK inhibitors?Presenters:Jeff P. Sharman, MD (chair)Medical DirectorHematology ResearchUS Oncology Willamette Valley Cancer InstituteEugene, Oregon Matthew S. Davids, MD, MMScAssociate Professor of MedicineHarvard Medical SchoolDirector of Clinical ResearchDivision of LymphomaDana-Farber Cancer InstituteBoston, MassachusettsAnthony Mato, MD, MSCEAssociate ProfessorDivision of LeukemiaMemorial Sloan Kettering Cancer CenterNew York, New YorkContent based on an online CME program supported by an educational grant from Lilly. For further information concerning Lilly grant funding, visit https://bit.ly/3wXOsV5. Link to full program:https://bit.ly/3NEpsYQ

There are no comments yet.

Please log in to write the first comment.